By coinnews 
00:00 Speaker A
We’re checking in on healthcare stocks. The sector’s been under pressure this year, facing headwinds on multiple fronts. Yahoo Finance senior health reporter Anjalee Khemlani is here with the latest. So, Anjalee, outside of the pharmaceutical health stocks, which who knows what’s going to happen with those sector specific tariffs, what are the signals that Wall Street’s kind of looking at in the sector?
00:25 Anjalee Khemlani
Well, that’s what they’re looking for is signals. And that’s actually the reason why we’re talking about this. We’ve seen, of course, that the pharma sector has been big on some of the uncertainty with tariffs and not knowing what is going to be impacting them. But in the non-pharma sector, we’re seeing a few signals for some interesting stocks. You’re seeing, um, you know, pressure from the government, whether it is the tariffs or research funding cuts have been one of the big ones that are impacting both biotechs as well as clinical research organizations. I’ve been taking a look at some of those stocks and what it means for sort of the long term. We know biotechs have been under pressure for the last couple of years as interest from investors wane, and that’s what’s causing the volatility from, you know, the broader markets to really catch up to an area that had been kind of, you know, defensive for a while. You take a look at how the biotech sector has been stacking up. It’s been kind of sad for them for a little bit. Um, so take a look at one of the stocks. I wanted to look at Medpace earlier this week. Really, uh, uh, interesting numbers. They, they were a little softer on their earnings numbers. And so they got a lot of questions from the analysts on the call about what is happening for them. They are clinical research organization. And so they help biotechs do a good job. You can see that huge dip, um, that came up. And then now it’s kind of trading flat and a little bit up since then. And that’s because on the fundamentals, you know, they were covered based on this is a cyclical kind of stock. Take a look at Intuitive Surgical. That’s another area. So medtech definitely getting hit by these tariffs. They were not carved out. And so it’s forcing analysts to think a little bit more, uh, specifically about what goes into some of these, uh, devices, as well as how companies are thinking about these tariffs. You see the huge spike because the numbers looked good. They had a beat. And then questions about having to invest, uh, two billion dollars, the impact on the company from the tariffs, uh, and then looking to invest in manufacturing. So you can see that kind of volatility coming together, and it’s making a really interesting earnings season for us and something we really need to continue watching.
03:37 Speaker A
It’s fascinating, especially monitoring who’s giving guidance with how much confidence they’re giving guidance and saying essentially, this could change at any second at the moment. Thank you so much.
03:52 Anjalee Khemlani
Yes. Pretty much.